4 completed. 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Completed 4 |
Follow Biofrontera Bioscience GmbH: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy Study for the Treatment of Non-Aggressive Basal Cell Carcinoma With Photodynamic Therapy BF-200 ALA, methyl-aminolevulinate - Basal Cell Carcinoma (BCC) | Phase 3 | Completed | Biofrontera Bioscience GmbH | 281 | 2014-01-28 | 2022-11-03 |
| Safety and Efficacy Study for the Field-directed Treatment of Actinic Keratosis (AK) With Photodynamic Therapy (PDT) BF-200 ALA gel, Placebo to BF-200 ALA gel, Photodynamic therapy with BF-RhodoLED - Actinic Keratosis | Phase 3 | Completed | Biofrontera Bioscience GmbH | 87 | 2013-10-01 | 2023-07-28 |
| Evaluation of Safety and Efficacy of BF-200 ALA for the Treatment of Actinic Keratosis With Photodynamic Therapy BF-200 ALA, MAL Cream, Vehicle - Actinic Keratosis | Phase 3 | Completed | Biofrontera Bioscience GmbH | 571 | 2008-04-01 | 2017-04-28 |
| Evaluation of Efficacy and Safety of BF-200 ALA Used With Photodynamic Therapy in Patients With Actinic Keratosis. Vehicle, BF-200 ALA - Actinic Keratosis | Phase 3 | Completed | Biofrontera Bioscience GmbH | 122 | 2007-12-01 | 2017-04-06 |
Keratosis, Actinic (3) · Carcinoma, Basal Cell (1)
Aminolevulinic Acid (4) · BF-200 ALA (3) · methyl 5-aminolevulinate (2) · 1-phenyl-3,3-dimethyltriazene (1) · Photochemotherapy (1)
Germany (2)
Colin Morton, Dr. (1) · Rolf M. Szeimies, Prof. Dr. (1) · Rolf-Markus Szeimies, Prof Dr (1) · Thomas Dirschka, Prof. Dr. (1) · Uwe Reinhold, Prof. Dr. (1)